

Date: October 19, 2026

To,

**The Manager – Listing
Dept of Corp. Services,
BSE Limited
P.J. Towers, Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: 543593**

**The Manager – Listing
National Stock Exchange of India Ltd.
Exchange plaza, Bandra Kurla Complex
Bandra East
Mumbai – 400 051
Symbol: DBOL**

Dear Sir/Mam,

Subject: Disclosure under Regulation 30 of The SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")
Re: Execution of Technology Licensing Agreement with Planetary SA, Switzerland

In furtherance to our earlier intimation dated January 21, 2026, regarding the execution of a non-binding term sheet with Planetary SA, Switzerland, we wish to inform you that Dhampur Bio Organics Limited ("DBO" or "the Company") has entered into a Technology Licensing Agreement with Planetary SA, Switzerland ("Planetary") on October 19, 2026 at 2:30 pm (IST) for the exclusive production of Mycoprotein in India.

The disclosure pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, are furnished in Annexure A.

You are requested to take the above information on record.

Yours sincerely,

For Dhampur Bio Organics Limited

Ashu

Rawat

Ashu Rawat

Company Secretary & Compliance Officer

Digitally signed by
Ashu Rawat
Date: 2026.10.19
17:39:27 +05'30'

Details with respect to Regulation 30 read with Schedule III of the Listing Regulations and SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026

Details of Technology Licensing Agreement

i	Name of the entity(ies) with whom agreement/ ~~JV/ Term sheet~~ is signed;	The Technology Licensing Agreement has been executed between:- 1. Dhampur Bio Organics Limited (“DBO”) and 2. Planetary SA, Switzerland (“Planetary”)
ii	Area of agreement/ ~~JV/ Term sheet~~ ;	The Technology Licensing Agreement sets out the major terms for the below arrangement between the parties: i. Construction and operation of Mycoprotein production infrastructure by DBO following a synergetic license-based collaboration model. Planetary shall be the technology provider and off taker of the Mycoprotein and related products and DBO shall be the manufacturer and supplier of the Mycoprotein and related products; and ii. To execute a commercialisation and offtake agreement, iii. To execute a joint venture agreement to establish a Joint Venture Company between parties to undertake commercialization and offtake of Mycoprotein in India
iii	Domestic/International;	Planetary SA is a Switzerland based company. The manufacture of Mycoprotein using the technology license will be undertaken in India.
iv	Share exchange ratio / JV ratio;	Not Applicable
v	Scope of business operation of agreement/ ~~JV/ Term sheet~~ ;	Same as point ii
Vi	Details of consideration paid / received in agreement/ ~~JV/ Term sheet~~ ;	Licensing Fee/ Royalty 10% of after-tax revenue as defined in this Agreement, paid quarterly by DBO to Planetary. One Time launch fee- Planetary shall charge DBO for engineering, launch, installation, commissioning, process training and handover support on an open-book basis until completion, as mutually agreed

		between parties. DBO shall also pay a one-time IT setup fee to planetary for the configuration of the Data Platform.
vii	Significant terms and conditions of agreement/ JV/ Term sheet in brief; Type text here	Key Obligations of Planetary: To provide licensed intellectual property and specified licensed services; engineering, launch, installation, commissioning and initial training support; maintenance and enforcement of licensed intellectual property; and agreed technical support, subject to the terms of the Agreement. Key Obligations of DBO: To use the licensed intellectual property only for the project and at the approved facility; payment of fees and royalties; compliance with confidentiality, access-control, audit, reporting and intellectual-property protection obligations; and obtaining required approvals for its performance. Term: Unless earlier terminated in accordance with the provisions of this Agreement, the agreement shall be for an initial term of 10 (ten) years from the Effective Date. Upon mutual written agreement between the Parties, the Agreement may be renewed for one or more successive terms of 5 years.
viii	Whether the acquisition would fall within related party transactions and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at “arm’s length”;	This arrangement does not involve any related party transaction.
ix	Size of the entity(ies);	Not Applicable
x	Rationale and benefit expected.	The Technology to be used for production of Mycoprotein products has synergy with the existing business of the company and forward integration step wherein sugar and molasses will act as feedstock for production of Mycoprotein. By entering into this business, the Company will introduce a new revenue stream for the Company and will be able to increase its profitability.